ARK Invest's position in WGS, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 1,175,238 | $61.0M | 0.84% | #36 |
| ARKG | 618,157 | $32.1M | 1.62% | #22 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-05 | ARKG | Buy | Added | 15,765 | $1.0M |
| 2026-11-04 | ARKG | Buy | Added | 25,758 | $1.8M |
| 2026-11-03 | ARKG | Buy | Added | 3,409 | $234K |
| 2026-11-02 | ARKG | Buy | Added | 17,865 | $1.1M |
| 2026-09-14 | ARKK | Sell | Trimmed | 22,586 | $2.0M |
| 2026-09-11 | ARKK | Sell | Trimmed | 7,631 | $651K |
| 2026-08-06 | ARKK | Buy | Added | 19,509 | $1.4M |
| 2026-08-06 | ARKG | Buy | Added | 12,685 | $883K |
| 2026-08-05 | ARKK | Buy | Added | 34,528 | $2.4M |
| 2026-08-05 | ARKG | Buy | Added | 22,491 | $1.6M |
| 2026-08-04 | ARKK | Buy | Added | 54,632 | $3.9M |
| 2026-08-04 | ARKG | Buy | Added | 18,736 | $1.3M |
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx…
See WGS's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open WGS on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.